Heather Wakelee
Publications
- A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol. 2012; (10): 1574-82
- Lung cancer incidence in never smokers. J Clin Oncol. 2007; (5): 472-8
- A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. J Thorac Oncol. 2013; (2): e17-8
- A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. J Natl Compr Canc Netw. 2013; (4): 389-94
- Aflibercept in lung cancer. Expert Opin Biol Ther. 2013; (1): 115-20
- Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. Anticancer Drugs. 2013
- A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012; (4): 1013-20
- A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Br J Cancer. 2012; (4): 604-11
- A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2012; (3): 825-34
- A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2012; (3): 815-24
- A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 2012; (1): 57-62
- Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer. 2012; (3): 410-5
- ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer. 2012; (2): 421-6
- Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Cancer Invest. 2012; (3): 231-5
- Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer. 2012; (1): 52-8
- Metastatic non-small cell lung cancer management: novel targets and recent clinical advances. Clin Adv Hematol Oncol. 2012; (4): 226-34
- The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2012; (2): 563-71
- Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys. 2012; (1): 231-7
- XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012; (1): 219-26
- American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011; (15): 2121-7
- Current management of small cell lung cancer. Clin Chest Med. 2011; (4): 853-63
- Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked. Cancer Epidemiol Biomarkers Prev. 2011; (3): 545-54
- Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2011; (5): 920-6
- A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010; (11): 1821-5
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2010; (2): 376-81
- Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res. 2010; (7): 2167-75
- Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol. 2009; (5): 850-6
- Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. 2009; (5): 289-304
- Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol. 2009; (3): 429-31
- Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs. 2009; (6): 597-605
- Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California. Cancer Epidemiol Biomarkers Prev. 2009; (8): 2248-55
- Adjuvant chemotherapy for resected non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2008; (3): 198-203
- Antibodies to vascular endothelial growth factor in non-small cell lung cancer. J Thorac Oncol. 2008; (6 Suppl 2): S113-8
- Complications of ablative therapies in lung cancer. Clin Lung Cancer. 2008; (2): 122-6
- Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer. 2008; (2): 85-91
- Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2008; (6): 346-51
- Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer. 2008; (1): 9-15
- Lung cancer presenting with amegakaryocytic thrombocytopenia. J Clin Oncol. 2008; (7): 1171-4
- Sex differences in lung-cancer susceptibility: a smoke screen? Lancet Oncol. 2008; (7): 609-10
- Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008; (6 Suppl 2): S107-12
- Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. J Thorac Oncol. 2007; (7 Suppl 3): S125-7
- Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007; (2): 328-33
- Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease. Oncologist. 2007; (3): 331-7
- Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007; (1): 15-27
- A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma. Clin Lung Cancer. 2006; (2): 146-8
- An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006; (5): 1507-14
- Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer. 2006; (10): 2208-17
- Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer. 2006; (1): 18-21
- Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response. Clin Lung Cancer. 2006; (1): 22-9
- Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2006; (8): 802-9
- Second- and third-line treatments in non-small cell lung cancer. Curr Treat Options Oncol. 2006; (1): 37-49
- Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc). 2006; (6): 387-98
- Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006; (5): 441-6
- A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. Invest New Drugs. 2005; (3): 241-2
- Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Clin Lung Cancer. 2005: S6-12
- Docetaxel in advanced non-small cell lung cancer. Expert Rev Anticancer Ther. 2005; (1): 13-24
- Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist. 2005: 1-10
- Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol. 2005; (24): 5613-9
- Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer. 2005; (3): 389-97
- Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer. 2005: S31-8
- Novel approaches for the treatment of small cell lung cancer. Hematol Oncol Clin North Am. 2004; (2): 499-518
- Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am J Physiol. 1996; (5 Pt 1): C1544-55
Help
Trial Administration